# NRG-BR002: metastasis-directed ablation in limited metastatic breast cancer

Source: https://onco.cc/trials/nrg-br002/  
OnCo record `nrg-br002` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NRG-BR002 did not meet its progression endpoint for added metastasis-directed ablation in a selected breast-cancer population. The planned phase 3 portion did not proceed.

## Summary

The 2026 report analysed 125 eligible participants among 129 enrolled. Most had HR-positive, HER2-negative disease; 93 percent of ablation was SBRT. The study compared first-line systemic treatment alone with the same approach plus treatment of visible metastases.

Progression-free survival was measured from randomisation. The trial did not show a statistically significant progression-free or overall-survival improvement and did not proceed to phase 3. The captured registry lists completed status. These findings do not erase palliation or establish the effect in every breast subtype or other disease setting.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-11-09
- Also known as: NRG BR002
- Tags: education-audit; local-treatment
- Registry id: NCT02364557
- Phase: 2/3
- Setting: Breast cancer with no more than four metastases, controlled primary and no progression on up to twelve months of first-line systemic therapy: standard care with or without metastasis-directed SBRT/surgery
- Sponsor: NRG Oncology
- Enrolled: 129
- Result: Progression-free survival hazard ratio 0.92, 95 percent confidence interval 0.57 to 1.47; overall-survival hazard ratio 1.07, interval 0.60 to 1.89.
- Outcomes: Progression-free survival from randomisation, eligible 2026 analysis: Systemic therapy plus ablation 19.5 months vs Systemic therapy without ablation 23 months, HR 0.92

## Sources

- ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364557
- Primary 2026 report: https://pubmed.ncbi.nlm.nih.gov/42842849/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- key papers: [NRG-BR002: metastasis-directed ablation during first-line therapy for limited metastatic breast cancer](https://onco.cc/key-papers/paper-nrg-br002-jco-2026/)
- people: [Eleftherios P. Mamounas](https://onco.cc/people/eleftherios-mamounas/)

---
JSON: https://onco.cc/api/v1/entities/nrg-br002.json